Skip to content
Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals

CRNX

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics for endocrine diseases and endocrine-related tumors.

Market cap
$8.87B+224%
Revenue$18.1M+2,278%
Net income-$496.4M-51.2%
Free cash flow-$419.5M-55.6%
EPS (diluted)-$5.13-34.7%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$14.8M
EPS estimate-$1.23

Financials

Q1 2026

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation & ratios

Valuation

See full
Market cap$8.87B+224%
Enterprise value$8.81B+211%
P/S491.2×-1,548×

Profitability

See full
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Segments

By segment

See full
Reportable Segment$10.7M+2,873%

By product

See full
Collaboration and license revenue$428.0K+18.6%

Competitors

Profile

Crinetics Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics for endocrine diseases and endocrine-related tumors. The company leverages a proprietary platform to target G protein-coupled receptors (GPCRs) with orally available treatments designed to replace traditional injectable therapies. Their core value proposition lies in improving patient quality of life through biochemical control and treatment convenience.

Competitive position

A pioneer in oral GPCR-targeted endocrine therapies, transitioning from a clinical-stage R&D firm to a commercial-stage organization with a first-in-class oral treatment for acromegaly.

GeographiesUnited States, European Union, Japan
Customer segmentsSpecialized healthcare providers, Rare disease patients, Health insurance payers
Business modelR&D-based drug development, Direct product sales, Licensing and royalties
SuppliersContract manufacturing organizations, Raw material suppliers, Clinical research organizations
CustomersSpecialty pharmacies, Wholesale distributors, Healthcare systems
Listed2018
Employees210.0
CEOR. Scott Struthers
FilingsSEC EDGAR

Questions, answered.

What is Crinetics Pharmaceuticals's market cap?
Crinetics Pharmaceuticals (CRNX) has a market capitalization of $8.9B and trades on NASDAQ.
What is Crinetics Pharmaceuticals's revenue and profitability?
Crinetics Pharmaceuticals generated $18.1M in trailing twelve-month revenue with a net loss of $496.4M, representing a net margin of -2747.2%. Gross margin stands at 150.0%, with free cash flow of -$419.5M. These figures are based on the Q1 2026 filing.
Who are Crinetics Pharmaceuticals's competitors?
Crinetics Pharmaceuticals's key competitors include Neurocrine Biosciences, Corcept Therapeutics Inc., Xeris Biopharma Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Crinetics Pharmaceuticals partner with?
Crinetics Pharmaceuticals's notable partners include Sanwa Kagaku Kenkyusho Co., Ltd., Ipsen, Novartis.
Where is Crinetics Pharmaceuticals headquartered?
Crinetics Pharmaceuticals is headquartered in United States of America and employs approximately 210 people. It has been publicly traded since 2018.